Novavax | NVAX - Interest Expense On Debt


Novavax reported $4.24M in Interest Expense on Debt for its fiscal quarter ending in September of 2024.





Interest Expense On Debt Change Date
Adma Biologics USD 1.68M 150K Sep/2025
Agenus USD 12.8M 7.89M Mar/2025
AstraZeneca USD 484M 181M Dec/2025
BioCryst Pharmaceuticals USD 24.45M 381K Dec/2024
Cassava Sciences USD 129.73M 5.65M Sep/2025
Geron USD 7.3M 1.35M Dec/2025
GlaxoSmithKline GBP 188M 21M Dec/2025
MannKind USD 13.87M 6.54M Dec/2025
Merck USD 412M 85M Dec/2025
Minerva Neurosciences USD 2.31M 60K Jun/2024
Moderna USD 12.14B 12.13B Sep/2025
Novartis USD 281M 8M Sep/2025
Novavax USD 4.24M 96K Sep/2024
Pfizer USD 711M 59M Dec/2025
Sanofi EUR -25M 252M Dec/2025
Sarepta Therapeutics USD 7.56M 2.33M Sep/2025
TG Therapeutics USD 6.53M 187K Dec/2025